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Controlling gene expression via small interfering RNA (siRNA) has opened the doors to a plethora of therapeutic
possibilities, with many currently in the pipelines of drug development for various ocular diseases. Despite the
potential of siRNA technologies, barriers to intracellular delivery significantly limit their clinical efficacy. However,
recent progress in the field of drug delivery strongly suggests that targeted manipulation of gene expression via
siRNA delivered through nanocarriers can have an enormous impact on improving therapeutic outcomes for
ophthalmic applications. Particularly, synthetic nanocarriers have demonstrated their suitability as a customizable
multifunctional platform for the targeted intracellular delivery of siRNA and other hydrophilic and hydrophobic
drugs in ocular applications. We predict that synthetic nanocarriers will simultaneously increase drug bioavailability,
while reducing side effects and the need for repeated intraocular injections. This review will discuss the recent
advances in ocular siRNA delivery via non-viral nanocarriers and the potential and limitations of various strategies
for the development of a ‘universal’ siRNA delivery system for clinical applications.
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Challenges of posterior segment ophthalmic therapeutics
Pharmaceutical treatment of retinal degenerative dis-
eases affecting the posterior segment of the eye is
made challenging by restrictive blood ocular barriers
such as the blood aqueous barrier (BAB) and the
blood retinal barrier (BRB), which separate the eye
from systemic circulation [1]. Additionally, the com-
partmentalized structure of the eye limits the passage
of therapeutics from the anterior chamber to the pos-
terior segment, which houses the light-sensing retina
[2]. Finally, once the drug successfully enters the back of
the eye, effective clearance mechanisms act to rapidly clear
the delivered molecules [2]. In conjunction, these barriers
render posterior segment ophthalmic drug delivery par-
ticularly challenging. Figure 1 provides a schematic repre-
sentation of the various physical delivery barriers as well
as the clearance mechanisms, which effectively expel
drugs that successfully enter the eye.* Correspondence: thakurajit@gmail.com
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reproduction in any medium, provided the orLocal and systemic routes for drug delivery
It is estimated that following instillation, only 5% of
topically applied drugs enter the anterior chamber of the
eye, either through trans-corneal permeation (Figure 1,
arrow 1) or non-corneal permeation into the anterior uvea
through the conjunctiva and sclera (Figure 1, arrow 2) [2].
Increasing the residence time on the eye through viscous
formulation can slightly improve uptake. However, due to
the physical barrier created by the corneal and conjunc-
tival epithelium, and the relatively small tear volume
(~7 μl) available [3], a maximal attainable absorption
into the anterior chamber appears to be approximately
10% of the applied dose [4]. Drugs are eliminated from
the aqueous humor via aqueous turnover through the
Schlemm’s canal and trabecular meshwork (Figure 1,
arrow 4) and by uptake into systemic circulation through
uveoscleral blood flow (Figure 1, arrow 5) [2]. Elimination
via the first route occurs through convective flow at a rate
of approximately 3 μl/min and is independent of drug
type. Clearance through uveal blood flow however, is
influenced by the ability of the drug to penetrate the
endothelial walls of the blood vessels. Thus, lipophilic
drugs clear more rapidly than hydrophilic drugs, oftenLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Schematic representation of the various routes of ocular drug delivery and drug elimination from the eye. 1) trans-corneal
permeation, 2) non-corneal drug permeation, 3) drug delivery to the anterior chamber via the BAB, 4) drug elimination from the anterior
chamber via the trabecular meshwork and Sclemm’s canal, 5) drug elimination from the anterior chamber into the uveoscleral circulation, 6)
drug delivery to the posterior chamber via the BRB, 7) intravitreal drug delivery, 8) drug elimination from the vitreous via the BRB, 9) drug
elimination from the vitreous via the anterior route. Reproduced with permission from Elsevier [2].
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physical barrier created by the lens, flow of drugs from
the anterior chamber to the posterior segment of the
eye is negligible. Therefore, topical drug administration
is typically limited to anterior complications. The sys-
temic route is also severely limited in its ability to effect-
ively deliver drugs to the back of the eye. Only an
estimated 1 – 2% of compounds delivered via this route
successfully cross the BAB (Figure 1, arrow 3) and the
BRB (Figure 1, arrow 6) and accumulate within the ret-
inal tissues [1]. With many newly developed pharma-
ceuticals being protein-based, oral formulations become
increasingly difficult to administer, as the drugs need to be
protected from degradation within the gastro-intestinal
tract. Furthermore, the large concentrations of drug
required to achieve therapeutically relevant concentra-
tions within the retinal tissues and the increased poten-
tial for off-target interactions makes oral administration
an undesirable route of delivery for posterior segment
therapies.
There are numerous potential sites surrounding the
eye that can house solid drug releasing scaffolds for loca-
lized treatment, as illustrated in Figure 2. [3]. Periocular
instillation that does not require perforation of the eye
wall is desirable as it can minimize invasiveness. How-
ever, approaches that utilize this route require drugs topass through several layers, including the episclera,
sclera, choroid Bruch’s membrane and retinal pigment
epithelium (RPE), in order to reach the vitreous chamber
and the retina [5]. Therefore, due to poor penetration
into the posterior segment, this route of delivery lacks
clinical significance to date [4]. Subconjunctival injec-
tions represent an attractive option for delivery of drugs
to the choroid as the sclera is highly permeability to
large molecules; however, this approach is less appealing
for drug delivery to the retina as the compound must
still cross the choroid and the RPE [4].
Intravitreal drug delivery
The most efficient means to deliver drugs into the pos-
terior segment is through direct injection into the vitre-
ous cavity (Figure 1, arrow 7) [5]. Using a high-gauge
needle, therapeutics may be introduced into the vitreous
through simple injection, producing high concentrations
of drug locally surrounding the retinal tissues while lim-
iting off-target exposure. However, the concentration of
drug is rapidly depleted from the posterior segment via
permeation across the BRB (Figure 1, arrow 8) and by
diffusion across the vitreous to the anterior chamber
(Figure 1, arrow 9), which allows drugs to be cleared
through the anterior route [2]. Thus, repeat injections
are required, often every 4 – 6 weeks, to maintain
Figure 2 Potential sites for placement of a drug releasing scaffold in the eye. An illustration of the numerous potential sites for placement
of a drug releasing scaffold for sustained ocular delivery. Reproduced with permission from Nature Publishing Group [3].
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segment [6]. Repeat instillations are associated with
increasing risk of injection-related complications, such as
raised intraocular pressure, vitreous or retinal hemorrhage,
retinal detachment, retinal tears, endophthalmitis, cat-
aracts, floaters and transient blurry vision [5]. Rates of
endophthalmitis and cataract formation per injection
are 0.2% and 0.05% respectively [5]. Repeat injections
are also associated with patient discomfort and adherence
issues [1]. Therefore, while intravitreal injections have the
greatest clinical efficacy, they are also the most risky.
Currently, the most promising solutions to combat
the challenges of posterior segment drug delivery are
approaches that successfully utilize direct intravitreal
delivery and sustain therapeutic concentrations for
extended periods of time, thereby decreasing the frequency
of intervention. The first commercially successful sus-
tained release intravitreal device for treatment of cyto-
megalovirus retinitis was Vitrasert (Bausch and Lomb), a
non-degrading implant that is surgically implanted at the
pars plana [5]. Vitrasert is a US Food and Drug Adminis-
tration (FDA) approved drug delivery system, which con-
sists of a tablet of ganciclovir coated with polyvinyl alcohol
(PVA) and ethylene vinyl acetate (EVA) [5]. The imperme-
able EVA coating limits the surface area through which
ganciclovir can release, forcing drug to diffuse through the
small PVA rate-limiting membrane, slowing the release
and allowing treatment for a period of 5 to 8 months [1].
However, Vitrasert is a relatively large non-degradingdevice and therefore requires an incision for introduction
into the vitreous cavity, as well as a secondary surgical
intervention for device removal following exhaustion of
the drug reservoir. The I-vation (Surmodics) drug delivery
system is another example of a non-degrading, sustained
intravitreal release device for the treatment of diabetic
macular edema. The helical construct was designed to fa-
cilitate ease of implantation and removal, maximize sur-
face area available for drug release, and allow sutureless
anchorage within the vitreous [7]. The titanium helix is
coated with a blend of poly(methyl methacrylate) and
EVA, which is loaded with triamcinolone acetonide and
provides sustained release for 18–36 months [5,8]. In con-
trast, the Iluvien (Alimera Sciences) drug delivery system
consists of a very small cylindrical polyimide rod loaded
with fluocinolone acetonide (FAc) capable of being
injected through a 25-gauge needle and releasing low
levels of drug for up to 3 years [5,8]. However, as this scaf-
fold is composed of non-degrading materials and is not
fixed to the eye wall, it is expected to remain within the
patient’s orbit following depletion of the drug and is cur-
rently under review by the FDA [9]. Ozurdex (Allergan),
an FDA approved dexamethasone loaded intravitreal insert
for the treatment of macular edema and noninfectious
uveitis, is another scaffold capable of introduction into the
vitreous via minimally invasive injection using a 22-gauge
applicator [7]. However, unlike Iluvien, Ozurdex is com-
posed of degradable poly(lactide-co-glycolide) [10], thereby
allowing scaffold degradation and clearance from the eye
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vention [11].
With recent advances in pharmaceuticals, including
regulatory approval of multiple pharmacotherapies to
treat wet age-related macular degeneration (AMD), and
the increasingly elderly demographic at risk of degenera-
tive eye disorders, there has been renewed interest in
designing novel drug delivery platforms, particularly
nanocarriers, to address the limitations of posterior seg-
ment therapeutics [3]. Furthermore, scientific research is
continuing to shed new light on the fundamental bio-
chemical pathways implicated in retinal degenerative
diseases, which is leading to the discovery of new
pharmacological targets and the development of novel
therapeutics.
RNA interference and siRNA delivery
RNA interference (RNAi) is an evolutionarily conserved
mechanism that has been observed in most organisms
from plants to vertebrates. It is a mechanism that leads
to sequence-specific post-transcriptional gene silencing
that was first documented in animals by Andrew Fire
and Craig Mello in 1998, both of whom subsequently
received the Nobel Prize in Physiology or Medicine in
2006 [12,13].
RNA interference can provide a novel therapeutic mo-
dality to treat many human diseases by interfering with
disease-causing and disease-promoting genes in a se-
quence-specific manner. Elbashir et al. were the first to
demonstrate that small interfering RNA (siRNAs) can
induce the RNAi pathway in mammalian cells without
producing an adverse immune response [14]. This im-
mediately suggested that the RNAi pathway could poten-
tially be manipulated in humans for the treatment of
many human diseases. Theoretically, RNAi can be used
to selectively alter the expression of any transcribed
gene. This new paradigm in therapeutics allows one to
address disease states previously considered ‘undrug-
gable’ [15]. In addition, it creates new opportunities to
alter important cellular processes such as cell division
and apoptosis, both of which are significantly altered in
many cancers [16].
RNA interference is essentially a conserved cellular
mechanism that leads to post-transcriptional gene silencing,
which can be manipulated for therapeutic applications in
humans. Post-transcriptional gene silencing strategies can
be broadly divided into four types: 1) single-stranded anti-
sense oligodeoxynucleotides (ODNs)- synthetic molecules
that can specifically hybridize with complementary mRNA
and sterically inhibit protein translation, 2) ribozymes-
catalytically active small RNA molecules that can spe-
cifically recognize and cleave single-stranded regions
in RNA, 3) microRNA (miRNA)- endogenous, short
double-stranded non-coding RNA molecules that play animportant role in health and disease by modulating gene
expression, and 4) siRNAs- these 18–25 nucleotide long
duplexes are potent activators of the innate immune sys-
tem that have been shown to initiate sequence-specific
post-transcriptional gene silencing. Although all of these
strategies can potentially be applied to suppress mRNA
translation, it is generally accepted that siRNA technology
offers the best combination of specificity, potency and ver-
satility as a therapeutic [15]. In addition, siRNAs are easily
synthesized and do not require cellular expression systems
or complex protein purification systems, making this tech-
nology significantly more cost effective over other small
molecule therapeutics [12].
Small-interfering RNA mediates its post-transcriptional
gene silencing effects via the RNAi pathway. In brief,
when exogenous siRNA duplexes are introduced into
mammalian cells, the 5’-end is phosphorylated. This
duplex is then assembled into a multiprotein complex
called RNA-induced silencing complex (RISC), which
includes proteins such as Argonaute 2 (AGO2), Dicer,
TRBP (HIV-1 TAR RNA-binding protein) and PACT
(dsRNA-binding protein) [17]. The sense strand is then
cleaved and unwound, leaving only the antisense strand
associated with AGO2. Argonaute 2 is an endonuclease
that promotes hybridization of this antisense strand to
complementary cellular mRNAs and subsequent cleavage
of the mRNA target [17]. This results in ‘knocking down’
the translation of the target gene [18].
In designing siRNAs, the three most important attri-
butes to be taken into account are: potency (effectiveness
of gene silencing at low siRNA concentrations), specificity
(minimize homology to other mRNAs) and nuclease
stability (resistance against exonuclease and endonuclease
activity). Moreover, there are two types of off-target effects
that should be minimized: immune stimulation arising
from siRNA recognition by the innate immune system,
and unintended silencing of genes that share partial
homology with the siRNA [15,17].
It is clear that siRNA technology has a great thera-
peutic potential in medicine. However, one of the major
limitations for their application in vitro and in vivo is
the inability of siRNA to cross cell membranes and reach
the cytoplasm. The negative charges arising from the
phosphate groups in the siRNA backbone electrostati-
cally repel negatively charged cell membranes, therefore
limiting siRNA ability to diffuse across cell membranes.
In addition, other challenges common to most drug de-
livery systems, including high molecular weight, short
blood half-life, poor specificity and uptake in target tis-
sues, cellular toxicity, and undesirable off-target effects,
significantly hamper the successful application of siRNA
therapeutics in medicine [12]. Moreover, the intrinsic
physical barriers, efficient drug clearance mechanisms
and other complexities of ocular tissues such as the
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siRNA delivery. In order to address these problems, several
siRNA delivery strategies have been developed for in vitro
and in vivo applications.
Numerous non-viral carriers including natural and
synthetic polymers, polyplexes, liposomes, lipoplexes,
peptides, dendrimers and free nucleic acid pressurized
hydrodynamic injections, as well as virus-based vectors
and plasmids encoding for siRNA, have been proposed for
siRNA delivery. Although most of these strategies have
been attempted with various degrees of success in vitro
and in vivo, strategies for targeted siRNA delivery that are
most relevant to ophthalmic applications will be reviewed.
Non-viral siRNA delivery systems
In an evolutionary sense, the prevalence of viral infec-
tion of cells has likely resulted in highly efficient cellular
and systemic defense mechanisms aimed at degrading
the naked siRNA molecule in vivo. Serum nucleases
such as eri-1 [19], renal clearance, and nontargeted bio-
distribution make intracellular targets extremely difficult
to access. Thus, the most prohibitive barrier faced by
siRNA therapeutic strategies is a delivery system [20].
Traditionally, engineered viral particles were tasked with
the delivery of nucleic payloads to the eye due to its rela-
tive immune-privilege status [21]. Several viral types,
particularly adenovirus (Ad), adenoassociated virus
(AAV), and lentivirus, are being actively investigated as
vectors for RNAi therapy [22]. Exotic modifications of
these viral vectors, such as self-complementary AAV
(scAAV) or helper-dependent adenovirus (HD-Ad), are
the current state-of-the-art in viral delivery, optimizing
the properties of earlier generations for ocular gene de-
livery [23]. However, viral vectors are seen as an accept-
able rather than perfect solution to nucleic acid delivery;
the potential for mutagenesis, limited loading capacities,
appropriate targeting, insertional predictability, high pro-
duction costs, and adverse immune reactivity severely limit
the practicability of viruses [24]. Alternatively, deliveringFigure 3 Nanocarriers for ocular siRNA delivery. This illustration shows
polymer, B) liposome, C) protein, D) dendrimer. The siRNA payload is typic
interior to preserve its bioactivity, reduce non-specific cellular uptake and pplasmid vectors expressing siRNA have been attempted
with success [25-27], but such DNA-based expression vec-
tors can potentially integrate into the host genome and in-
crease the chances of insertional mutagenesis [26,28].
Engineered, non-viral siRNA delivery systems are being
extensively studied because they are relatively safe and can
be easily modified with targeting ligands. These artificial
vectors are therefore seen as an attractive alternative
for viral delivery systems. There are four main types of
vectors that are convenient for non-viral siRNA delivery: 1)
polymeric, 2) lipid, 3) protein and 4) dendrimeric nano-
carrier delivery systems (Figure 3).
1) Polymeric nanocarriers
Although many types of polymers have been used to de-
liver oligonucleotides, much attention has focused on
using cationic polymers for two main reasons: 1) their
ability to electrostatically bind siRNA without the need for
covalent attachment or encapsulation, and 2) the ability of
amine containing cationic polymers to provide endosomal
buffering and escape for intracytosolic siRNA delivery.
Polyethylenimine (PEI) is perhaps the most investigated
synthetic cationic polymer for nucleic acid delivery due to
its uniquely high buffering capability at endosomal pH,
known as the ‘proton sponge’ effect, which releases nu-
cleic acid payloads into the cytoplasm after endocytosis
[29]. Grayson et al. have demonstrated that polyplexes of
PEI can effectively deliver siRNA to cells in vitro [30]. Kim
et al. were among the first to employ the use of pegylated
(PEG) PEI-siRNA cationic polyplexes targeted against vas-
cular endothelial growth factor-A (VEGFA), vascular
endothelial growth factor receptor-1 (VEGFR1) and/or
VEGFR2 to significantly reduce herpes simplex virus-
induced angiogenesis and stromal keratitis in murine ocu-
lar tissues in vivo [31]. Notably, these PEG-PEI-siRNA
polyplexes were effective in both local and systemic ad-
ministration of the formulation. Given that PEI-siRNA
has been successfully tested in vivo for the treatment offour types of pegylated nanocarriers for ocular siRNA delivery: A)
ally entrapped, encapsulated or covalently bound to the nanocarrier
revent undesirable activation of the innate immune system.
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rier for ocular siRNA delivery [32].
Alternatively, polymeric micelles have been extensively
used to deliver nucleic acids. These micelles are colloidal
suspensions of amphiphilic copolymers with particle sizes
ranging from 5–100 nm [12]. For siRNA delivery, it has
been suggested that PEG-polycation diblock copolymers,
lactosylated PEG-siRNA and PEG-poly(methacrylic acid)
blor siRNA encapsulation are well suited [12]. Interest-
ingly, Duan et al. have combined the use of a cationic ock
co-polymers fdiblock copolymer (PEI-PEG) with a natural
polysaccharide, chitosan, to make ‘ternary’ nanocarriers to
successfully deliver siRNA targeted against the IkB kinase
subunit mRNA to human Tenon’s capsule fibroblasts
in vitro [33]. The authors demonstrated that these bio-
degradable nanocarriers significantly enhanced siRNA de-
livery and were much less toxic than 25KDa PEI alone. In
addition, Ye et al. applied these ‘ternary’ siRNA nanocar-
riers targeting IkB kinase subunit mRNA in vivo in a mon-
key model of glaucoma filtration surgery and showed that
subconjunctival injection of these nanocarriers signifi-
cantly reduced scar tissue compared to controls [34].
Taken together, these results suggest that pegylated cat-
ionic nanocarriers may be suitable candidates for ophthal-
mic siRNA delivery.
2) Lipid nanocarriers
There are many types of lipid-based siRNA delivery
systems. However, the most common approaches in-
clude: 1) liposomal delivery, where siRNA is encapsu-
lated within vesicles composed of a phospholipid bilayer
and 2) lipoplexes, where siRNA complexes with cationic
lipids (such as 1,2-dioleoyl-3-trimethylammonium-
propane (DOTAP), 1,2-dioleoyl-sn-glycero-3-phosphati-
dylethanolamine (DOPE), N-[1-(2,3-dioleyloxy)propyl]-N,
N,N-trimethylammonium chloride (DOTMA) and N,N-
dioleyl-N,N-dimethylammonium chloride (DODAC)) and
forms nanoscale complexes. Liposomes are probably the
most commonly used artificial gene delivery vector since
their ability to transport the preproinsulin gene to the liver
was demonstrated nearly 30 years ago [35]. Liu et al. have
successfully demonstrated that 132 nm pegylated lipo-
some-protamine-hyaluronic acid nanocarriers loaded with
siRNA targeted against VEGFR1 can not only enhance
VEGFR1 knockdown, but also accelerate intracellular de-
livery to human RPE cells over free siRNA in vitro [36].
After intravitreal administration, these nanocarriers were
also able to significantly reduce the area of choroidal
neovascularization (CNV) in a laser-induced murine
CNV model with minimal toxicity, suggesting their suit-
ability for clinical applications [36]. Lipid combinations
such as DC-Chol (3β-[N-(N′,N′-dimethylamino-ethane)
carbamoyl]-cholesterol) have also been used to deliversiRNA successfully and may present opportunities to
combine desired features to create novel lipid-based
nanocarriers [37].
3) Protein nanocarriers
Protein-based siRNA delivery involves the formation of
‘proticles,’ where proteins are conjugated (electrostatically
or covalently) to siRNA for delivery. For example, albumin-
protamine-oligonucleotide forms nanocarrier complexes
(230–320 nm diameter), which can be safely delivered to
cells [38]. Recently, Johnson et al. have developed a novel
cell-penetrating peptide (CPP) for ocular delivery of small
and large molecules, including siRNA, fluorescent probes,
plasmid DNA and quantum dots to RPE, photoreceptor
and ganglion cells in vitro and in vivo [39]. Not only do the
authors report >50% transgene silencing after peptide-
siRNA delivery in human embryonic retinal cells in vitro,
but they also demonstrate that this peptide-based nanocar-
rier can transduce approximately 85% of the neural retina
within 2 h of intravitreal injection in vivo [39]. The lack of
toxicity, biodegradability and serum stability of these nano-
carriers makes them particularly advantageous as a delivery
vehicle [38]. However, protein-based nanocarriers have
been known to localize and degrade within endolysosomes
after cellular uptake [40]. This problem will likely require
additional nanocarrier design considerations such as
endosomal escape strategies for its successful applica-
tion in ocular conditions.
4) Dendrimers
Dendrimers represent a group of nanoscale materials
that are hyperbranched, monodisperse and have defined
molecular weights. Structurally, dendrimers are composed
of a central core, repeating units that make up the
branches, and surface functional groups [27]. Dendrimers
are synthesized in a step-by-step fashion by the sequential
addition of repeating units organized in concentric layers,
called generations, around the central core. High gener-
ation dendrimers have numerous cavities within their
hyperbranched structure to allow for the encapsulation of
therapeutic agents such as siRNA molecules. The most
common dendrimers used for siRNA delivery include poly
(amidoamine) (PAMAM) and poly(propylene imine) (PPI)
[41]. However, other types of dendrimers composed of
amine-containing cationic polymers such as poly-L-lysine
have been investigated for ODN (anti-VEGF) delivery to
RPE cells in vitro [42], and have demonstrated long-term
(4–6 months) inhibition (up to 95%) of laser-induced
CNV after intravitreal injection in a rat model, without
any observable adverse effects [43]. The major advantages
of dendrimers include biodegradability, ease of synthesis
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functional groups to optimize siRNA delivery. Recently,
Agrawal et al. have developed dendrimer-conjugated mag-
netofluorescent nanoworms called ‘dendriworms’ that sig-
nificantly enhance intracellular siRNA delivery in a mouse
model by optimizing endosomal escape [44]. Alternatively,
Han et al. have conjugated CPPs, such as HIV transactiva-
tor of transcription (TaT), to PAMAM dendrimers for
enhanced intracellular siRNA delivery in vitro and in vivo
[45]. Together, these results suggest that dendrimers are
ideally suited to serve as nanocarriers, which can be
loaded with siRNA and functionalized with PEG and tar-
geting ligands for clinical applications. However, at
present, there are no examples of dendrimeric siRNA de-
livery for ocular applications in the literature.
Despite the multitude of siRNA delivery strategies
available, the lack of safe and efficient delivery in vivo
has limited the clinical translation of siRNA therapeu-
tics. Although a few siRNA therapeutic drugs are cur-
rently under clinical trials (Table 1, [46-55]) for ocular
applications, none have yet been approved by the FDA.
Hence, there is a clear need to develop safe and effica-
cious methods of ocular siRNA delivery.
Chemically modified siRNAs
Various molecular locations on siRNA molecules can be
chemically altered to resist hydrolysis and enhance cellular
uptake. In order to increase the efficacy of siRNA delivery,
much research has focused on increasing the nuclease re-
sistance and therefore serum stability of siRNAs. Nucleases
such as eri-1 are involved in the degradation of unmodified
siRNA duplexes [19], which have been reported to have a
short serum half-life of about 3–5 min. However, it has
been shown that siRNA serum half-life can be extended
up to 72 h with fully modified duplexes [56].
Among the multitude of possible siRNA modifications,
there are two schools of thought regarding the best ap-
proach to developing chemically modified siRNA. In one
approach, it is believed that extensive chemical modifica-
tion of siRNA is most likely to lead to the greatest efficacy.
For example, Sirna Therapeutics has several patents and
products that favour extensive siRNA duplex modifica-
tions, where the sense and antisense strands have modi-
fied bases (2’-Fluoro-RNA pyrimidines (2’-F-RNA), DNA
purines), altered covalent links between the nucleotides
(phosphorothioate linkage (PS)) and inverted 5’ and 3’ aba-
sic end caps [17]. These extensive siRNA modifications
translated into increased potency and a much longer
serum half-life (48–72 h) in a Hepatitis B virus mouse
model [56]. In contrast, the other school of thought is fo-
cused on creating stabilized siRNAs with minimal modifi-
cations. For example, Alnylam Pharmaceuticals has many
siRNA products that are selectively modified (2’-sugar
modifications such as 2’-O-methyl or 2’-F-RNA) atvulnerable sites, such as those susceptible to endonuclease
cleavage [15,17,57]. It is important to note that modifica-
tions to the RNA backbone can potentially impair siRNA-
induced silencing activity, thus many reported modifica-
tions have been limited to the sense strand [58,59]. How-
ever, the rules for predicting siRNA stability and potency
are still unclear since some studies have demonstrated
antisense modifications with preserved siRNA functional-
ity [60,61], while other studies have shown sense strand
modifications with reduced siRNA efficiency [62,63].
Various chemical modifications to the terminals, back-
bone, nucleobases and sugars of siRNAs can be implemen-
ted to protect the duplex from exonuclease degradation.
For example, the phosphodiester (PO4) linkages along the
RNA backbone can be replaced with PS or boranopho-
sphonate (PB) at the 3’ end [64-66]. It has been shown that
PS derived oligonucleotides stimulate the physical uptake
of siRNA in human cells [67], while siRNAs with PB back-
bone modifications have less cytotoxicity and a much
higher nuclease resistance than native siRNA. Such PB
siRNAs are at least 10 times more nuclease resistant than
unmodified siRNAs, and have recently been used to treat
patients with AMD. The process has reached Phase II clin-
ical trials, and it was found to have no observable side
effects [68]. Replacement of sugar moieties at the 2’-
hydroxyl group of the ribose backbone with 2’-O-methyl,
2’-fluoro, or 2’-methoxyethyl groups can further improve
in vivo stability [66,69]. Moreover, various molecules can
be conjugated to the 5’ or 3’ ends of the sense strand,
without affecting the activity of the antisense strand
needed for silencing [66]. This method can allow for cell
specific targeting or visualization of siRNA uptake and
distribution by introducing appropriate ligands and
fluorophores respectively. However, degradation of these
artificially altered siRNA molecules may result in metabo-
lites with unsafe or otherwise unwanted reactivity [66].
Chemical modification of siRNA can increase stability in
biological solutions, target specificity and potency [68].
However, the benefits of modification must be measured
against the cost and labour of the modification process, as
well as its effects on immune stimulation, which are gen-
erally difficult to predict and require empirical testing
in vivo.
Immune stimulation and other off-target effects of siRNA
delivery
In addition to the gene knockdown effects of the RNAi
pathway, there are many other potential consequences
that can be initiated by siRNA in vivo. Hence, these so
called ‘off-target effects’ need to be considered and eval-
uated in any siRNA delivery study. For example, it is
well known that double stranded RNA (dsRNAs) greater
than 30 bp are potent activators of the innate immune
response [70]. Although siRNA duplexes are shorter
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off-target effects [58,71]. In general, RNAs are recog-
nized by three major types of immunoreceptors: Toll-
like Receptors (TLR), protein kinase R (PKR) and heli-
cases. Toll-like receptors are found on cell-surfaces
(TLR3) and in endosomes (TLR3,7,8), whereas PKR and
helicases (MDA5, RIG-I) are found in the cytoplasm
[72,73]. Immune recognition can lead to a host of down-
stream effects at the cellular level, including cytokine re-
lease, interferon response and changes in gene expression.
At the whole body level, the use of unmodified siRNAs
have been known to induce systemic toxicity, increase
serum transaminases, decrease body weight, lymphopenia
and piloerection [74]. Thus, proper siRNA design should
likely incorporate features to minimize the possibility of
undesirable immune activation.
Although immune activation is influenced by many
factors such as oligonucleotide length, sequence, chem-
ical modification, mode of delivery and immune cell type
involved, it has been previously shown that chemically
modified siRNAs can be synthesized so as to reduce
their immunostimulatory properties [74]. However, it is
interesting to note that immune stimulation may also
have desirable consequences, such as anti-angiogenesis
via the TLR3 pathway [72]. Although this type of thera-
peutic immune stimulation may be useful from the
standpoint of treating cancer, it can also have potentially
severe side-effects [73].
In addition to immune stimulation, other off-target
effects can originate from the partial hybridization of theFigure 4 Nanocarrier uptake and intracellular siRNA delivery. This illus
occurs via receptor-mediated endocytosis. The key step in cytoplasmic siRNA
endosomal escape. A ‘smart’ nanocarrier can induce endosomal escape by lys
also be used to trigger the dissociation of the nanocarrier, therefore releasingantisense strand of siRNA with an unintended mRNA.
This may lead to the cleavage and subsequent knock-
down of the wrong gene [75]. In addition, siRNAs can
have their sense strand incorporated into RISC, leading
to other off-target effects [75]. To address these pro-
blems, siRNA sequences can be carefully selected to
minimize complementarity with unwanted mRNAs, and
chemically modified siRNAs can be used to increase the
selective incorporation of the antisense strand into RISC
[62,76]. This highlights the importance of proper siRNA
design in mediating target gene knockdown.
Cellular uptake of nanocarriers and endosomal escape
strategies
Cells can uptake nanocarriers in many ways, including
phagocytosis, macropinocytosis, clathrin-mediated endo-
cytosis, non-clathrin-mediated endocytosis and caveolin-
mediated uptake [77]. Each of these pathways delivers
nanocarriers to specific cellular compartments, which
may help or hinder drugs (intracellular, membrane-
impermeable type) from reaching their target site. For
example, cationic-lipid-DNA complexes and nanocarriers
with ligands for glycoreceptors are internalized via clathrin-
mediated endocytosis and are destined for the lysosomal
compartment (Figure 4) [77]. In contrast, nanocarriers with
ligands such as albumin, folic acids and cholesterol are
taken up via caveolin-mediated endocytosis, while cell-
penetrating peptide (CPP) ligands such as the HIV transac-
tivator of transcription (TaT), facilitate uptake via macropi-
nocytosis [78,79]. In addition to the surface ligand, the sizetration shows that uptake of antibody targeted nanocarriers (10–100 nm)
delivery involves low pH-triggered nanocarrier disassembly and
ing or fusing with endolysosomes upon acidification. The pH change can
the siRNA cargo into the cytosol.
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ism and rate of uptake. Previous nanocarrier uptake studies
by Rejman et al. have shown that untargeted particles up to
200 nm are exclusively internalized via clathrin-mediated
endocytosis, while larger particles enter via a caveolin-
dependent pathway [80]. Furthermore, they report an in-
verse correlation between particle size and rate of uptake.
For example, as the particle size was raised from 50 nm to
100 nm, internalization was diminished by 3–4 times.
Interestingly, their data also suggests that cells have an
upper limit for the size of internalized particles, since 1 μm
particles were not taken up into mouse melanoma B16 cells
in vitro [80].
After internalization of nanocarriers into cells, many
studies have shown that large fractions of these nanocar-
riers can remain sequestered in trafficking vesicles and
endolysosomes [81]. This implies that some types of
nanocarriers may not be suitable for delivering mem-
brane-impermeable therapeutics (such as siRNA) to
intracellular targets. Moreover, a lysosomal localization
of unmodified naked siRNA will likely result in the deg-
radation of siRNA [79]. Hence, much research has fo-
cused on intracellular delivery strategies such as cationic
lipid transfection, microinjection and electroporation
[82]. However, most of these strategies are limited to
in vitro conditions due to their invasiveness, variable
transfection efficiency, complexity of the procedure and
potential for altering/disrupting cellular function. Recent
efforts have demonstrated that endosomal escape strat-
egies can be incorporated into nanocarrier design to sig-
nificantly enhance cytosolic delivery of siRNA [83]. Most
commonly, CPPs, pH responsive polymers, fusogenic
peptide sequences and hydrophobic molecules have been
used for nanocarrier endosomal escape [83]. Nanocar-
riers functionalized with CPPs such as the TaT, VP22,
penetratin and polyarginine have been shown to perme-
ate through the plasma membrane for direct cytoplasmic
delivery [83-86]. Alternatively, other pH-responsive
approaches tend to induce the ‘proton-sponge effect’ for
endosomal escape via the clever use of cationic proton-
able amine-containing polymers such as PEI [87]. In this
approach, PEI acts as a buffer against endolysosomal
acidification and causes the osmotic swelling and rup-
ture of endolysosomes, releasing the nanocarriers into
the cytosol (Figure 4) [88]. In contrast, other approaches
attempt to conjugate drugs to fusogenic peptide
sequences, such as GALA and KALA, or hydrophobic
molecules such that the nanocarrier can traverse mem-
branes [83]. For example, cholesterol-tagging has been
shown to improve cytosolic delivery of siRNA with min-
imal cytotoxicity [89].
Interestingly, lipid-based nanocarriers can also be engi-
neered to fuse with cell membranes, either avoiding endo-
cytosis completely or escaping endolysosomes withoutinducing endolysosomal lysis. Although some studies sug-
gest that a net positive surface charge and a high cationic
lipid/siRNA molar charge ratio are important factors
required to facilitate efficient membrane fusion with lipid-
based nanocarriers, it has been reported that these factors
also seem to significantly increase toxicity [90]. Recently,
Leal et al. have reported the development of cationic lipo-
some (CL)-siRNA complexes with novel cubic phase
nanostructures, which offer a novel solution to lipid based
delivery. Cubic phase lipid delivery systems readily fuse
with cell membranes due to their high charge density and
positive Gaussian modulus, delivering their cargo through
transiently induced pores in the endosomal membrane,
which results in highly efficient gene silencing in vitro
with low toxicity [91,92]. In contrast, some studies have
successfully employed non-invasive physical methods to
enhance intracellular delivery of siRNA. For example, Du
et al. recently demonstrated that simultaneous administra-
tion of low intensity ultrasound or 15-20% microbubbles
can safely enhance the delivery efficiency of siRNA-loaded
polymeric nanocarriers to rat RPE-J cells in vitro [93]. It is
likely that a combination of approaches will need to be
tested to determine the optimal strategy for endosomal es-
cape for ocular siRNA delivery.
Development of a ‘universal’ nanocarrier for ocular siRNA
delivery
To achieve intracellular ocular siRNA delivery via intra-
vitreal injection, a rational design of a nanocarrier is
required that is capable of overcoming the unique bio-
logical barriers present in the eye. A review of the litera-
ture suggests that several important features including
targeting, stealth, siRNA incorporation, size, shape and
surface characteristics will have to be taken into consid-
eration for the development of a ‘universal’ nanocarrier
for ocular siRNA delivery (Table 2). Turchinovich et al.
recently demonstrated efficient siRNA delivery into
mouse retina in vivo using a commercially available
transfection reagent [94]. However, this non-targeted
method mainly transfected the retinal ganglion cell layer.
This suggests that it is likely necessary to use targeting
molecules on nanocarriers to control the specific retinal
cell type being targeted for transfection. Other studies
by Aggarwal et al. have shown that nanocarriers exposed
to biological fluids in host tissues such as serum are im-
mediately coated with opsonins and other host proteins,
creating a ‘molecular signature’ that determines the
internalization pathway and fate of nanocarriers taken
up by phagocytic cells [95]. Given these observations,
many approaches to shield the nanocarriers from such
host-induced modification have been developed, among
which, a hydrophilic coat of PEG has demonstrated its
effectiveness in vivo. These PEG coated ‘stealth’ nanocar-
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Figure 5 Schematic of a four-component ‘universal’ nanocarrier for ocular siRNA delivery. This illustration highlights the salient features of
a four-component, targeted core-shell nanocarrier for ocular siRNA delivery.
Thakur et al. Journal of Biological Engineering 2012, 6:7 Page 12 of 16
http://www.jbioleng.org/content/6/1/7specific cellular uptake and opsonization by phagocytic
cells [96].
Moreover, the use of a nanocarrier allows for the control
of immune stimulation. Kleinman et al. have shown that
siRNA can directly mediate CNV suppression in vivo via a
non-RNAi mediated mechanism involving cell-surface re-
ceptor TLR-3 [72]. A therapeutic siRNA shielded from the
ocular environment can perhaps avoid such immune
stimulation effects of siRNA. However, in some cases, it
might be desirable to induce a potentially beneficial im-
mune stimulation effect such as angiogenesis suppression.
Given the versatility of nanocarrier systems, it is likely
possible to design a carrier that exposes chemically modi-
fied, stabilized siRNA to ocular fluids to mediate innate
immune stimulation and trigger the TLR-3 pathway for
angiogenesis suppression.
A review of successful siRNA delivery nanocarriers
in vivo strongly suggests that a four component core-shell
delivery system is ideal: 1) core- composed of a biodegrad-
able material that entraps, encapsulates or covalently binds
siRNA, 2) shell- composed of a hydrophilic polymer such
as PEG or a self-protein such as albumin for stability, pro-
tection and surface charge modification, 3) drug- chem-
ically modified siRNA for enhanced stability, potency,
specificity and efficacy, 4) targeting ligand- antibody,aptamer, peptide, lectin or other small molecules present
on the nanocarrier surface for selective delivery to target
cells (Figure 5). In addition, the size, shape and surface
characteristics of the nanocarrier are key elements that con-
trol their biological interactions. Although the ideal size
and shape of nanocarriers for ocular drug delivery have not
been systematically tested, the diffusion of nanocarriers
through solid tumor models suggest that smaller carriers
are preferred over larger ones. Wong et al. have recently
provided proof-of-principle that gelatin nanocarriers can be
designed to change their particle size from 100 nm to
10 nm upon reaching the tumor microenvironment,
responding to locally produced matrix metalloproteinase-2
(MMP-2), and can thus penetrate deeper into the tumor
tissue [97]. Although most studies involving nanocarrier
biodistribution and cellular uptake have been elucidated
using spherical nanocarriers, recent studies suggest that the
shape of nanocarriers can significantly influence their bio-
logical interactions [79,98]. Particularly, a recent study
showed that positively charged cylindrical particles with an
aspect ratio of 3 (150 nm x 450 nm) were internalized four
times more rapidly by HeLa cells than cylindrical particles
with an aspect ratio of 1 (200 nm x 200 nm) [98]. This sug-
gests that it is important to consider the size as well as the
shape of the nanocarrier in their design. Nanocarrier
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controlled by manipulating their surface characteristics.
The predominant strategy for improving the stability of
nanocarriers in biological solutions has involved the graft-
ing of PEG to the surface to render them more hydrophilic
and neutral in charge [79]. Some studies suggest that the
addition of self-proteins such as albumin via adsorption or
covalent modification may reduce non-specific cellular up-
take and opsonization [99,100]. Taken together, these data
suggest that it is important to optimize the size, shape and
surface characteristics for the development of a ‘universal’
nanocarrier for ocular siRNA delivery.
The proposed four-component nanocarrier system
provides a customizable platform for the development of
a ‘smart’ drug delivery system that can be engineered to
enhance endosomal escape, control siRNA release intra-
cellularly and manipulate the innate immune response.
Particularly, a core-shell nanocarrier structure allows for
the incorporation of specific endosomal escape strat-
egies, which can be activated upon endocytosis. For ex-
ample, the core and shell components can be joined
with a cleavable linker that is sensitive to endolysosomal
stimuli such as acidic pH and acid-activated proteases.
This design effectively allows for the de-shielding of the
nanocarrier core, containing siRNA, to induce endoso-
mal destabilization, or to directly traverse the endosomal
membrane if the core has a hydrophobic composition.
The reducing environment of the cytosol can also be
used to further stimulate the dissociation of siRNA from
the nanocarrier core via the incorporation of disulphide
bonds. The first successful systemic delivery of siRNA
via a targeted nanocarrier in humans serves to confirm
these important parameters in nanocarrier design [101].
Conclusions and future directions
Given that we currently lack an ideal siRNA delivery system
for ocular disorders, it is instructive to consider the nucleo-
tide delivery strategies found in nature. For example, viruses
are essentially targeted biological nanocarriers for the local
or systemic delivery of nucleic acids, known to be the
causative agents of various human diseases. A virion is in-
deed a smart nanocarrier, with several key features: envir-
onmental stability, monodispersity, bioresponsiveness,
biodegradability, immune modulation properties, endoso-
mal escape capabilities, intracellular replicative capacity,
and targeted and localized DNA/RNA intracellular delivery
to specific cells for controlling gene expression. To this ex-
tent, Breitbach et al. have recently shown that a modified
oncolytic pox virus administered intravenously in human
subjects can selectively target cancer cells in solid tumors,
without any observable clinical effects on normal cells
[102]. This 300 nm enveloped virus delivered ds-DNA to
target cells in a dose-dependent manner, similar to that
observed in the recent Phase I clinical trial with siRNA-nanocarrier technology [101]. A nature-inspired nanocar-
rier design can potentially provide structural insights into
developing the optimal solutions to some of the major bar-
riers in ocular and systemic siRNA delivery.
Many groups have employed ‘smart’ nanocarriers or
‘synthetic viruses’ that mimic isolated aspects of viral nu-
cleotide delivery with varying degrees of success. For ex-
ample, Hu et al. developed a pH-responsive core-shell
nanocarrier designed to release various cargos including
proteins, viral particles and siRNA under endosomal acid-
ification [103]. However, most of these single-stimuli re-
sponsive nanocarriers are focused on either drug delivery
or for diagnostic purposes (imaging and detection), with-
out the ability to combine such useful features. Although
multiple stimuli-responsive nucleotide delivery systems
are currently under development to address this challenge,
a general strategy for intracellular nucleotide delivery has
not yet been established [104]. This may be due to the fact
that nucleotide delivery systems vary greatly in their com-
position, such that combining beneficial features of two
different nucleotide delivery systems into a hybrid system
may not always be possible. In designing a nucleotide de-
livery system, it is instructive to note that viruses sequen-
tially deploy specific strategies to overcome each barrier at
the tissue and cellular level for successful intracellular nu-
cleotide delivery. It follows that any clinically viable nu-
cleotide delivery system will have to take into account the
common barriers to siRNA delivery and incorporate spe-
cific strategies to overcome each of these barriers, while
being flexible enough to combine features that can be
adapted to several ocular conditions.
We envision that the ultimate ocular siRNA delivery
system would incorporate a combination of nature-
inspired desirable features: a biodegradable, multiple stim-
uli-responsive nanocarrier for controlled and localized
siRNA release targeted to specific cell types for manipulat-
ing gene expression of specific genes. When combined
with a drug delivery device, such a ‘smart’ nucleotide deliv-
ery system would not only address the current challenges
of ocular siRNA delivery, with improved biodistribution,
bioavailability and reduced toxicity, but also improve
therapeutic outcomes for the patient.
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